Peter Milligan
Peter Milligan
Verified email at
Cited by
Cited by
Model‐based drug development
RL Lalonde, KG Kowalski, MM Hutmacher, W Ewy, DJ Nichols, ...
Clinical Pharmacology & Therapeutics 82 (1), 21-32, 2007
Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration
TJ Walsh, MO Karlsson, T Driscoll, AG Arguedas, P Adamson, ...
Antimicrobial agents and chemotherapy 48 (6), 2166-2172, 2004
Good practices in model‐informed drug discovery and development: practice, application, and documentation
EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ...
CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies
MO Karlsson, I Lutsar, PA Milligan
Antimicrobial agents and chemotherapy 53 (3), 935-944, 2009
Model‐based drug development: a rational approach to efficiently accelerate drug development
PA Milligan, MJ Brown, B Marchant, SW Martin, PH Van Der Graaf, ...
Clinical Pharmacology & Therapeutics 93 (6), 502-514, 2013
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children
TJ Walsh, T Driscoll, PA Milligan, ND Wood, H Schlamm, AH Groll, H Jafri, ...
Antimicrobial agents and chemotherapy 54 (10), 4116-4123, 2010
Models for time‐varying covariates in population pharmacokinetic‐pharmacodynamic analysis
U Wählby, AH Thomson, PA Milligan, MO Karlsson
British journal of clinical pharmacology 58 (4), 367-377, 2004
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction
PA Milligan, SF Marshall, MO Karlsson
British journal of clinical pharmacology 53, 45S-52S, 2002
Telephone follow‐up to improve glycaemic control in patients with type 2 diabetes: systematic review and meta‐analysis of controlled trials
L Wu, A Forbes, P Griffiths, P Milligan, A While
Diabetic Medicine 27 (11), 1217-1225, 2010
A pharmacokinetic‐pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether‐a‐go‐go‐related gene current inhibition data
DM Jonker, LA Kenna, D Leishman, R Wallis, PA Milligan, EN Jonsson
Clinical pharmacology & therapeutics 77 (6), 572-582, 2005
Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences
J Lippert, R Burghaus, A Edginton, S Frechen, M Karlsson, A Kovar, ...
CPT: pharmacometrics & systems pharmacology 8 (12), 878, 2019
The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA modeling and simulation workshop
E Manolis, S Rohou, R Hemmings, T Salmonson, M Karlsson, PA Milligan
CPT: pharmacometrics & systems pharmacology 2 (2), 1-4, 2013
PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST
EK Hansson, MA Amantea, P Westwood, PA Milligan, BE Houk, J French, ...
CPT: pharmacometrics & systems pharmacology 2 (11), 1-9, 2013
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and …
T Kerbusch, U Wählby, PA Milligan, MO Karlsson
British journal of clinical pharmacology 56 (6), 639-652, 2003
PKPD modeling of predictors for adverse effects and overall survival in sunitinib‐treated patients with GIST
EK Hansson, G Ma, MA Amantea, J French, PA Milligan, LE Friberg, ...
CPT: pharmacometrics & systems pharmacology 2 (12), 1-9, 2013
Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography
PA Milligan
Journal of Chromatography B: Biomedical Sciences and Applications 576 (1 …, 1992
Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development
MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ...
CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population …
T Kerbusch, PA Milligan, MO Karlsson
British journal of clinical pharmacology 57 (2), 170-180, 2004
Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children
TJ Walsh, TA Driscoll, AC Arietta, N Klein, J Bradley, H Jafri, H Schlamm, ...
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30, 2006
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients
L Claret, F Mercier, BE Houk, PA Milligan, R Bruno
Cancer chemotherapy and pharmacology 76, 567-573, 2015
The system can't perform the operation now. Try again later.
Articles 1–20